Home > Publications Database > Quality of Life in SMA Patients Under Treatment With Nusinersen. > print

001     164206
005     20240227115127.0
024 7 _ |a 10.3389/fneur.2021.626787
|2 doi
024 7 _ |a pmid:33854472
|2 pmid
024 7 _ |a pmc:PMC8039289
|2 pmc
024 7 _ |a altmetric:102924761
|2 altmetric
037 _ _ |a DZNE-2022-00862
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Mix, Lucas
|b 0
245 _ _ |a Quality of Life in SMA Patients Under Treatment With Nusinersen.
260 _ _ |a Lausanne
|c 2021
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709023021_12959
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Background: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to slow down or stop disease progression with a potentially major impact on patients' well-being. Objective: This study evaluates quality of life (QoL) in pediatric and adult patients over the course of therapy with nusinersen. Methods: Twenty-six SMA patients treated with nusinersen were evaluated regarding global QoL (gQoL), health-related QoL (HRQoL) and depressiveness. Assessments were conducted three times over the first 6 months of treatment. Applied were different questionnaires: the Anamnestic Comparative Self-Assessment (ACSA) for gQoL, the Short Form-36 Health Survey (SF-36) for HRQoL in adult patients and the ALS Depression Inventory 12 Items (ADI-12) for depressiveness. The sample was matched with 22 healthy controls. Results: Despite severe physical restrictions, patients reported high levels of QoL and low levels of depressiveness at study entry. Early disease onset and low levels of physical functioning were associated with better gQoL and lower levels of depressiveness. A significant decrease of gQoL in patients was evident over the course of the study. Still, adult patients reported a significant increase in perceived health. Conclusions: Our study provides first insight that SMA patients experience a gQoL superior to healthy controls at start of therapy. This might indicate patients' high hopes and expectations toward treatment. gQoL returns to a level similar to that of healthy controls over the course of therapy.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a antisense oligonucleotide
|2 Other
650 _ 7 |a depressiveness
|2 Other
650 _ 7 |a nusinersen (Spinraza)
|2 Other
650 _ 7 |a patient reported outcome
|2 Other
650 _ 7 |a quality of life
|2 Other
650 _ 7 |a spinal muscular atrophy
|2 Other
650 _ 7 |a well-being
|2 Other
700 1 _ |a Winter, Benedikt
|b 1
700 1 _ |a Wurster, Claudia
|0 P:(DE-2719)9002006
|b 2
|u dzne
700 1 _ |a Platen, Sophia
|b 3
700 1 _ |a Witzel, Simon
|0 P:(DE-2719)9001976
|b 4
|u dzne
700 1 _ |a Uzelac, Zeljko
|b 5
700 1 _ |a Graf, Heiko
|b 6
700 1 _ |a Ludolph, Albert C
|0 P:(DE-2719)2812633
|b 7
|u dzne
700 1 _ |a Lulé, Dorothée
|b 8
773 _ _ |a 10.3389/fneur.2021.626787
|g Vol. 12, p. 626787
|0 PERI:(DE-600)2564214-5
|p 626787
|t Frontiers in neurology
|v 12
|y 2021
|x 1664-2295
856 4 _ |u https://pub.dzne.de/record/164206/files/DZNE-2022-00862.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/164206/files/DZNE-2022-00862.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:164206
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)9002006
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)9001976
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812633
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-28
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT NEUROL : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-11T13:11:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-11T13:11:28Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-05-11T13:11:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-18
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center Ulm
|l Clinical Study Center Ulm
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000077
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21